Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Janux Therapeutics (JANX) Cash from Investing Activities (2021 - 2025)

Janux Therapeutics (JANX) has disclosed Cash from Investing Activities for 5 consecutive years, with $29.5 million as the latest value for Q4 2025.

  • On a quarterly basis, Cash from Investing Activities fell 12.92% to $29.5 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$301.0 million, a 16.65% decrease, with the full-year FY2025 number at -$301.0 million, down 16.65% from a year prior.
  • Cash from Investing Activities was $29.5 million for Q4 2025 at Janux Therapeutics, up from $8.3 million in the prior quarter.
  • In the past five years, Cash from Investing Activities ranged from a high of $33.9 million in Q4 2024 to a low of -$340.4 million in Q1 2025.
  • A 5-year average of -$44.1 million and a median of $4.4 million in 2021 define the central range for Cash from Investing Activities.
  • Peak YoY movement for Cash from Investing Activities: soared 20405.88% in 2022, then plummeted 1201.33% in 2024.
  • Janux Therapeutics' Cash from Investing Activities stood at $7.3 million in 2021, then crashed by 121.89% to -$1.6 million in 2022, then skyrocketed by 793.45% to $11.1 million in 2023, then surged by 205.01% to $33.9 million in 2024, then decreased by 12.92% to $29.5 million in 2025.
  • Per Business Quant, the three most recent readings for JANX's Cash from Investing Activities are $29.5 million (Q4 2025), $8.3 million (Q3 2025), and $1.6 million (Q2 2025).